Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis
This study is aimed at describing tofacitinib and baricitinib users by characterizing their prescription and healthcare histories, drug and healthcare utilization patterns, and direct costs from a healthcare system perspective. This retrospective cohort study was performed using Tuscan administrativ...
Saved in:
Main Authors: | Irma Convertino (Author), Valentina Lorenzoni (Author), Rosa Gini (Author), Giuseppe Turchetti (Author), Elisabetta Fini (Author), Sabrina Giometto (Author), Claudia Bartolini (Author), Olga Paoletti (Author), Sara Ferraro (Author), Emiliano Cappello (Author), Giulia Valdiserra (Author), Marco Bonaso (Author), Corrado Blandizzi (Author), Marco Tuccori (Author), Ersilia Lucenteforte (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
by: Irma Convertino, et al.
Published: (2023) -
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
by: Marco Tuccori, et al.
Published: (2020) -
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
by: Sara Ferraro, et al.
Published: (2019) -
Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation
by: Giulia Valdiserra, et al.
Published: (2023) -
Riluzole use in presence of contraindications in adults affected by amyotrophic lateral sclerosis and its off-label use in other motor neuron diseases: Findings from an Italian multicentre study (the CAESAR project)
by: Giada Crescioli, et al.
Published: (2022)